Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

Kozera, Emily; Flora, Akshay; Frew, John W

Kozera, Emily; Flora, Akshay; Frew, John W.

Kozera E; Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia.
Flora A; Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia.
Frew JW; Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia. Electronic address: john.frew@unsw.edu.au.

J Am Acad Dermatol ; 87(6): 1440-1442, 2022 Dec.

Article in English | MEDLINE | ID: covidwho-2220844

Subject(s)

Hidradenitis Suppurativa; Janus Kinase Inhibitors; Humans; Hidradenitis Suppurativa/drug therapy; Janus Kinase Inhibitors/adverse effects; Retrospective Studies; Heterocyclic Compounds, 3-Ring/therapeutic use

Keywords

Janus kinase; acne inversa; efficacy; hidradenitis suppurativa; safety; upadacitinib

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hidradenitis Suppurativa / Janus Kinase Inhibitors Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2022 Document Type: Article Affiliation country: J.jaad.2022.07.047

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google